Evidence map›Paper›PMID 41518660›Full record

ArticleChemistry & biodiversity2026

Hericenones From Hericium erinaceus (Bull.) Pers.: A Scoping Review of Structural Diversity and Health Benefits.

Ahmed Othman, Yhiya Amen, Kuniyoshi Shimizu

Abstract readScoping Review
In one paragraph

Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ahmed OthmanDepartment of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.ORCID https://orcid.org/0000-0002-2827-7621
Yhiya AmenDepartment of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.ORCID https://orcid.org/0000-0003-2552-4567
Kuniyoshi ShimizuDepartment of Agro-Environmental Sciences, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-5960-1503

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hericium erinaceus (Bull.) Pers., an edible and medicinal mushroom, has garnered significant scientific interest due to its rich array of bioactive compounds. Extensive research has highlighted the pharmacological properties of its constituents, including neuroprotective, neurotrophic, immunomodulatory, and anticancer activities. Among interesting bioactive secondary metabolites in H. erinaceus, hericenones-a structurally unique class of geranyl-resorcinol derivatives-have emerged as particularly promising pharmacological agents. This review comprehensively covers the 24 known natural hericenones and one semisynthetic derivative, detailing their structural elucidation with a focus on characteristic NMR spectroscopy to provide a systematic identification guide. Furthermore, the review discusses their biosynthesis, isolation methodologies, and beneficial biological properties. These include the stimulation of nerve growth factor (NGF), as well as anti-inflammatory, antioxidant, anticancer, antidiabetic, antiplatelet, and anti-obesity. By integrating chemical and pharmacological perspectives, this work underscores the promise of hericenones as lead compounds for the development of novel therapeutics.

Indexed as

HericiumAnimalsAnti-Inflammatory AgentsAntineoplastic AgentsAntioxidantsHumansHypoglycemic AgentsMolecular StructureNeuroprotective AgentsAnti-Inflammatory AgentsAntineoplastic AgentsAntioxidantsHypoglycemic AgentsNeuroprotective Agentsanticanceranti‐inflammatoryanti‐obesityantiplateletmushroomneurological agents

Identifiers

PMID41518660
PMCPMC13420232

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.